1-Phenyl-2-Pyridinyl Alkyl Alcohol PDE4 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for respiratory diseases like asthma and COPD have limitations due to undesirable side effects, such as nausea and gastric issues, and there is a need for compounds with high affinity for the PDE4 enzyme and improved solubility for effective therapeutic use.
Innovation Solution
Development of compounds of general formula (I) that act as PDE4 inhibitors, specifically 1-phenyl-2-pyridinyl alkyl alcohols with specific substituents, which exhibit high affinity for the PDE4 enzyme and good solubility, allowing for various administration routes including inhalation, oral, and transdermal delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation PDE4 inhibitors (rolipram, piclamilast) are used, then PDE4 enzyme inhibition is achieved, but side effects (nausea, emesis, gastric acid secretion) increase due to action on HPDE4 in CNS and parietal cells
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (1-phenyl-2-pyridinyl alkyl alcohol structure with particular substituents) that create selective interaction with LPDE4 binding site. This structural modification enables the compound to preferentially bind to LPDE4 in immune and inflammatory cells while avoiding HPDE4 in CNS and parietal cells, thus achieving local selectivity that reduces side effects while maintaining anti-inflammatory efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations on the 1-phenyl-2-pyridinyl alkyl alcohol core) to optimize the balance between PDE4 inhibition potency and selectivity for LPDE4. By adjusting these molecular parameters, the compounds achieve enhanced affinity for LPDE4 with reduced affinity for HPDE4, resolving the contradiction between efficacy and side effects.
2Reliability
If second-generation PDE4 inhibitors (roflumilast) are used to target LPDE4, then selectivity for immune and inflammatory cells is improved, but dosing must be reduced to achieve acceptable side effect profile, limiting therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by optimizing molecular structure parameters (substituent groups R1-R6, stereochemistry, and molecular weight) to achieve compounds with significantly enhanced LPDE4 selectivity compared to roflumilast. This structural optimization allows the compounds to maintain high therapeutic efficacy at lower doses, resolving the contradiction between selectivity and productivity by improving the therapeutic index.
Solution Approach 2:
The patent employs preliminary action by designing compounds with pre-optimized molecular features that anticipate and prevent the need for dose reduction. The 1-phenyl-2-pyridinyl alkyl alcohol structure with specific substituent patterns is designed beforehand to achieve superior LPDE4 selectivity, allowing full therapeutic dosing without the side effect limitations that constrain roflumilast.
3Adaptability or versatility
If PDE4 inhibitors are administered systemically, then broad distribution is achieved, but systemic side effects increase and therapeutic ratio decreases compared to inhalation route
Solution Approach 1:
The patent applies local quality by designing compounds with molecular properties (lipophilicity, molecular weight, and functional group configuration) that enable preferential accumulation in respiratory tissues when administered by inhalation. The 1-phenyl-2-pyridinyl alkyl alcohol structure with specific substituents creates local concentration gradients that favor lung tissue uptake, reducing systemic circulation and associated side effects while maintaining versatility in administration routes.
Data Source
AI summary
The present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to 1-phenyl-2-pyridinyl alkyl alcohol derivatives, to processes for the preparation thereof, compositions comprising them, combinations and therapeutic uses thereof.